Latest / The Well-Built Life / Insulin Evolution
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: and let's dive in. Welcome, listeners, to another engaging episode
- 0:28Speaker 1: of The Well-Built Life. I am Rachel, and today, we
- 0:32Speaker 1: dive into the fascinating journey of insulin, tracing its path
- 0:35Speaker 1: from discovery to our current advancements. And joining me is Thomas,
- 0:39Speaker 1: the resident expert on the nuts and bolts of this
- 0:42Speaker 1: incredible hormone. What's the first thing that comes to mind
- 0:45Speaker 1: when you think about insulin's discovery, Thomas?
- 0:48Speaker 2: Well, Rachel, think about it being like the first real
- 0:51Speaker 2: superhero in the fight against diabetes. Banting and Best's discovery
- 0:56Speaker 2: in 1921 was a game. Changer at the time. Diabetes
- 1:00Speaker 2: was practically a death sentence. Can you imagine the initial reactions?
- 1:05Speaker 1: Absolutely. If you look at the headlines from that era,
- 1:08Speaker 1: it was a seismic shift. The Toronto Daily Star actually
- 1:11Speaker 1: described insulin as the miracle cure, right? But the real
- 1:15Speaker 1: breakthrough was not just the idea, but the rigorous testing.
- 1:19Speaker 1: And then the first human trial in 1922. Can you
- 1:22Speaker 1: describe that pivotal moment?
- 1:24Speaker 2: Of course. The first patient was a 14-year-old boy named
- 1:29Speaker 2: Leonard Thompson. who was on his deathbed. Administering insulin to
- 1:33Speaker 2: him was a daring experiment, but the results were nothing
- 1:37Speaker 2: short of miraculous. His blood sugar levels dropped significantly, and
- 1:42Speaker 2: he began to gain weight. It was a turning point
- 1:45Speaker 2: that made global headlines, right, Rachel?
- 1:47Speaker 1: Exactly. Pretty wild when you look at the raw numbers.
- 1:51Speaker 1: From that initial success, it didn't just stop there. The
- 1:55Speaker 1: discovery sparked a flurry of research and innovation. Let's talk
- 1:59Speaker 1: about the 1950s to 1970s, when insulin started being extracted
- 2:05Speaker 1: from beef and pork. How did that impact treatment and accessibility?
- 2:10Speaker 2: It greatly improved availability. At the time, insulin was sourced
- 2:15Speaker 2: from animal pancreases, which made it a bit hit or miss.
- 2:19Speaker 2: It wasn't until the 1980s that recombinant DNA technology allowed
- 2:24Speaker 2: for the creation of human insulin, making it more standardized
- 2:27Speaker 2: and safer. But let's not forget the 1990s and early
- 2:32Speaker 2: 2000s when insulin analogs hit the market. These new formulations
- 2:37Speaker 2: led to even more precise control. How did that shift
- 2:40Speaker 2: the landscape, Rachel?
- 2:42Speaker 1: Right. That's a key evolution. Insulin analogs now cover a
- 2:46Speaker 1: spectrum of needs, from rapid, acting to ultra-long, acting. They
- 2:51Speaker 1: are designed to mimic the body's natural insulin, making management
- 2:55Speaker 1: more like clockwork. But these advancements come with their own challenges,
- 3:00Speaker 1: don't they? For instance, the basal bolus regimen.
- 3:04Speaker 2: Absolutely. It requires careful calculation and timing. One miscalculation can
- 3:10Speaker 2: throw off glucose control. And then to raise the debate,
- 3:14Speaker 2: is it better to use multiple injections or an insulin pump?
- 3:18Speaker 2: Each has its pros and cons. For example, pumps offer
- 3:22Speaker 2: flexibility but can be complex for new users.
- 3:25Speaker 1: That's a great point. Speaking of complexities, let's talk about
- 3:29Speaker 1: the cost. Insulin's price is a big concern, especially in
- 3:33Speaker 1: lower-income regions. It's not just about health access, it's ethical too.
- 3:39Speaker 1: How does that impact the broader narrative of diabetes management?
- 3:42Speaker 2: It's a tough ethical dilemma. On one hand, advancements are wonderful,
- 3:48Speaker 2: but on the other, we have to ask ourselves who
- 3:51Speaker 2: exactly is benefiting. And what's being done to make sure
- 3:54Speaker 2: that these medical miracles are accessible to everyone, not just
- 3:58Speaker 2: the wealthy?
- 3:59Speaker 1: Right. That's a pressing concern. As we look to the future,
- 4:03Speaker 1: technology is advancing. Continuous glucose monitors, insulin pumps, and AI-driven algorithms.
- 4:10Speaker 1: These are the tools that can really make a difference.
- 4:13Speaker 1: But what about the big picture? How do we ensure
- 4:15Speaker 1: that everyone, regardless of where they live or what they
- 4:18Speaker 1: can afford, gets the help they need?
- 4:21Speaker 2: Precisely. The future is promising, but it's also a challenge.
- 4:25Speaker 2: Policy changes, global collaborations, and a patient-centric approach are all crucial.
- 4:32Speaker 2: And we must remember, insulin is just one part of
- 4:35Speaker 2: the puzzle. It's about the holistic management of diabetes, which
- 4:39Speaker 2: involves diet, exercise, and mental health, too. The journey continues. So,
- 4:44Speaker 2: let's dive into the heart of it, insulin mechanisms and formulations.
- 4:49Speaker 2: We know insulin acts like a key that unlocks cells
- 4:52Speaker 2: for glucose to enter and be used as energy. But
- 4:55Speaker 2: how does this intricate process really work?
- 4:58Speaker 1: Exactly, and it's fascinating. Insulin is produced in the pancreas,
- 5:03Speaker 1: secreted by beta cells in the islets of Langerhans. When
- 5:07Speaker 1: blood glucose levels rise, beta cells release insulin into the bloodstream.
- 5:12Speaker 1: This hormone then binds to receptors on the surface of muscle, fat,
- 5:17Speaker 1: and liver cells. triggering a cascade of intracellular activities that
- 5:21Speaker 1: lead to glucose uptake and storage.
- 5:23Speaker 2: Right. It's like the pancreas is constantly gauging blood sugar levels,
- 5:28Speaker 2: much like a thermostat in a home. Once the level
- 5:31Speaker 2: is high enough, it initiates the release of insulin. But
- 5:34Speaker 2: we have different kinds of insulin each with its own
- 5:37Speaker 2: mechanism and timing.
- 5:38Speaker 1: Yes, the classes of insulin are crucial. Rapid. Acting insulins
- 5:43Speaker 1: like Lispro and Aspart act within minutes and peak after
- 5:46Speaker 1: 1 to 2 HRs. Think of them as quick, acting
- 5:51Speaker 1: security guards, ensuring glucose gets where it needs to go rapidly.
- 5:56Speaker 1: Then there are short, acting insulins like regular insulin, which
- 6:01Speaker 1: are stored as hexamers and act over a few hours.
- 6:05Speaker 1: More like a slower, steady security presence.
- 6:08Speaker 2: And then we have intermediate-acting NPH, long-acting Glargine, and ultra-long-acting Degludec.
- 6:15Speaker 2: These different phases allow for more precise control over blood
- 6:19Speaker 2: sugar levels, much like different layers of defense in a
- 6:22Speaker 2: security protocol. Basal insulins provide a steady baseline level, while
- 6:27Speaker 2: bolus insulins help manage post-meal spikes.
- 6:30Speaker 1: Absolutely. And the challenge in managing insulin, as you mentioned,
- 6:34Speaker 1: is in balancing the need for these different actions. Patients
- 6:38Speaker 1: have to carefully time and adjust their insulin dosages based
- 6:41Speaker 1: on meals and activity levels. which can be tricky.
- 6:44Speaker 2: That's true, and it's why insulin regimens can seem overwhelming.
- 6:48Speaker 2: Patients often struggle, especially those with type 1 diabetes who
- 6:52Speaker 2: require multiple daily injections. The introduction of insulin pumps has
- 6:56Speaker 2: made life easier for many, allowing for continuous, more flexible delivery.
- 7:00Speaker 2: But they come with their own set of issues, like
- 7:03Speaker 2: pump failures.
- 7:04Speaker 1: Exactly. An interesting contradiction. While insulin pumps offer precision and flexibility,
- 7:10Speaker 1: they are more complex and can be costly. Syringes and
- 7:14Speaker 1: traditional pens remain simpler but require more frequent injections, which
- 7:18Speaker 1: can be burdensome. It's the balancing act.
- 7:21Speaker 2: Yes, and the journey isn't just about insulin. It's a
- 7:24Speaker 2: comprehensive approach that includes diet, exercise, and mental health. But
- 7:29Speaker 2: the insulin itself is where the magic happens. Each type
- 7:32Speaker 2: has its role, and understanding these roles can significantly improve management.
- 7:36Speaker 1: True. The key is to understand these nuances and how
- 7:41Speaker 1: they interplay. The future looks promising with advancements in technology,
- 7:46Speaker 1: but we must also address the economic and environmental factors
- 7:51Speaker 1: that affect access and sustainability.
- 7:53Speaker 2: Absolutely. The path forward requires a holistic approach, ensuring equitable
- 7:59Speaker 2: access to these critical treatments and continuing to innovate in
- 8:02Speaker 2: the face of ongoing challenges. It's a journey, not a destination.
- 8:06Speaker 1: As we dig into the core dynamics of these stakeholders,
- 8:10Speaker 1: let's start with the medical researchers. They are the pioneers,
- 8:14Speaker 1: constantly pushing the boundaries of what we know about insulin.
- 8:18Speaker 1: What do you think, Thomas? How do their priorities and
- 8:21Speaker 1: challenges differ from those of the pharmaceutical companies?
- 8:25Speaker 2: Great question, Rachel. Medical researchers have an almost altruistic goal.
- 8:30Speaker 2: They are driven by the mission to understand and cure diseases,
- 8:33Speaker 2: including diabetes. They face the challenge of translating basic research
- 8:38Speaker 2: into clinical applications. For example, they might focus on developing
- 8:42Speaker 2: new insulin analogs with better absorption rates or side effects. Meanwhile,
- 8:47Speaker 2: pharmaceutical companies are driven by the bottom line. They want
- 8:51Speaker 2: to bring new products to market, generate profits, and stay competitive.
- 8:56Speaker 2: The tension here is in the speed of innovation versus
- 8:59Speaker 2: the cost and regulatory hurdles.
- 9:01Speaker 1: Exactly, and that's where we see the first major contradiction.
- 9:04Speaker 1: Researchers might prioritize slow, and thorough trials to ensure safety
- 9:09Speaker 1: and efficacy. Whereas pharma companies might push for faster approvals,
- 9:14Speaker 1: even at the cost of some safety margins, this creates
- 9:17Speaker 1: a complex landscape where ethical considerations meet commercial imperatives.
- 9:22Speaker 2: Right. Now let's flip to healthcare providers. They are on
- 9:26Speaker 2: the front line, dealing with patients daily. Their challenge is
- 9:30Speaker 2: to bridge the gap between cutting-edge research and practical patient care.
- 9:34Speaker 2: They must keep abreast of new protocols and technologies, but
- 9:38Speaker 2: also need the resources to implement them effectively. Patients, on
- 9:42Speaker 2: the other hand, are the direct beneficiaries, but they also
- 9:45Speaker 2: have to navigate the complexity of insulin management. This can
- 9:49Speaker 2: be daunting, especially for those with less support.
- 9:53Speaker 1: Very true. Patients face a daily battle with side effects,
- 9:57Speaker 1: insulin resistance, and the logistics of injections. They might feel
- 10:01Speaker 1: frustrated by the constant adjustments required and the burden of
- 10:04Speaker 1: remembering their insulin regimen. This is where the debate about
- 10:08Speaker 1: patient autonomy and education comes into play. Some argue that
- 10:12Speaker 1: more education and support are needed, while others believe that
- 10:16Speaker 1: overly complex technologies are might overwhelm patients.
- 10:20Speaker 2: Absolutely. The balance is tricky. On one side, we have
- 10:24Speaker 2: the need for sophisticated tools like continuous glucose monitors and
- 10:28Speaker 2: insulin pumps that can predict and adjust insulin levels automatically.
- 10:32Speaker 2: On the other, we have the risk of overwhelming patients
- 10:35Speaker 2: with too much technology, potentially leading to misuse or fear.
- 10:40Speaker 2: How do we strike that balance?
- 10:41Speaker 1: That's the crux, Thomas. It's about creating a system that's
- 10:45Speaker 1: robust enough to manage these challenges. but not so complex
- 10:49Speaker 1: that it alienates users. For instance, some patients might thrive
- 10:54Speaker 1: with advanced technology, while others might prefer traditional methods. The
- 10:59Speaker 1: key is personalized care and education, tailored to individual needs. Exactly.
- 11:04Speaker 2: This brings us to the environmental impact of insulin production.
- 11:08Speaker 2: The process of creating traditional insulin from animal sources or
- 11:12Speaker 2: synthetic recombinant DNA involves significant resource use and waste. Plus,
- 11:18Speaker 2: the potential for genetically modified organisms to escape into the
- 11:21Speaker 2: environment adds another layer of complexity. How do stakeholders balance
- 11:26Speaker 2: innovation with sustainability?
- 11:28Speaker 1: That's a critical debate angle. Pharmaceutical companies need to innovate,
- 11:33Speaker 1: but they also need to consider the environmental footprint of
- 11:35Speaker 1: their products. Medical researchers can contribute by exploring more sustainable
- 11:40Speaker 1: production methods, and patients can advocate for eco-friendly options. It's
- 11:46Speaker 1: a holistic approach that involves all parties.
- 11:48Speaker 2: Indeed. And speaking of holistic approaches, let's not forget the
- 11:52Speaker 2: economic access and disparities. Insulin is undoubtedly a necessity, but
- 11:56Speaker 2: its high cost can be prohibitive, especially in developing countries
- 12:00Speaker 2: or low-income populations. How do we ensure that everyone has
- 12:04Speaker 2: access regardless of their financial situation?
- 12:06Speaker 1: That's the final challenge to address. The policy landscape needs
- 12:10Speaker 1: to evolve to support affordable insulin access, whether through public
- 12:14Speaker 1: health programs, or international collaborations. Stakeholders must work together to
- 12:20Speaker 1: find solutions that prioritize patient needs without compromising on quality
- 12:25Speaker 1: or innovation.
- 12:26Speaker 2: Agreed. It's a multifaceted issue that requires collaboration and continuous improvement.
- 12:32Speaker 2: As we wrap up this section, let's emphasize the importance
- 12:35Speaker 2: of understanding these dynamics so we can support better outcomes
- 12:38Speaker 2: for all stakeholders involved in managing diabetes.
- 12:42Speaker 1: So, Let's look to the future and discuss emerging technologies
- 12:46Speaker 1: that could transform diabetes management and global health access to insulin. Thomas,
- 12:52Speaker 1: what do you think the biggest unsolved question is when
- 12:55Speaker 1: it comes to diabetes technology?
- 12:57Speaker 2: That's a great question, Rachel. One of the most pressing
- 13:00Speaker 2: is improving the consistency of insulin absorption and response. Right now,
- 13:06Speaker 2: the variability in absorption rates can lead to significant issues,
- 13:09Speaker 2: especially for individuals with irregular lifestyles or those needing precise
- 13:14Speaker 2: glucose management for conditions like pregnancy and breastfeeding.
- 13:18Speaker 1: Exactly, and that's a crucial challenge. On the tech side,
- 13:23Speaker 1: what advancements do you think could help us get closer
- 13:26Speaker 1: to a more consistent experience?
- 13:28Speaker 2: Well, advancements in continuous glucose monitoring CGM technology combined with
- 13:34Speaker 2: machine learning algorithms could potentially predict and adjust insulin delivery
- 13:38Speaker 2: more accurately. These systems could learn from an individual's patterns
- 13:42Speaker 2: and make real-time adjustments to keep glucose levels more stable.
- 13:46Speaker 1: That's wild when you look at the raw numbers. And
- 13:49Speaker 1: it's not just about making treatment more consistent, it's about
- 13:52Speaker 1: making it more personalized. Speaking of personalization, how do you
- 13:57Speaker 1: think the integration of artificial intelligence could benefit patients?
- 14:01Speaker 2: AI can personalize the management of insulin therapy by considering
- 14:05Speaker 2: a patient's unique physiological responses dietary habits, and activity levels.
- 14:11Speaker 2: It could optimize dosing and timing, reducing the risk of
- 14:15Speaker 2: hypoglycemic events and improving overall quality of life. But Thierry's
- 14:20Speaker 2: a flip side to how do we ensure that this
- 14:23Speaker 2: technology is approachable and usable for all levels of tech literacy.
- 14:27Speaker 1: That's a valid point. And Thierry's another area that's not
- 14:31Speaker 1: as glamorous but equally critical, making sure every patient has
- 14:36Speaker 1: access to the tools they need What does the future
- 14:39Speaker 1: look like for global health access to insulin, Thomas?
- 14:42Speaker 2: The future outlook is mixed. On one hand, we are
- 14:46Speaker 2: seeing more public-private partnerships that aim to lower insulin costs
- 14:50Speaker 2: and increase accessibility. But disparities remain stark. Insulin remains unaffordable
- 14:56Speaker 2: in many low-income regions. Policy innovations and international collaborations will
- 15:02Speaker 2: be key, but we need to ensure that these efforts
- 15:05Speaker 2: are sustained and effective.
- 15:06Speaker 1: Agreed. And even with better policies, the journey to equitable
- 15:11Speaker 1: access isn't just about price. It's about infrastructure and education.
- 15:16Speaker 1: Can you see any specific policy changes that could make
- 15:20Speaker 1: a significant difference?
- 15:21Speaker 2: Absolutely. Policy changes like subsidies for insulin and insulin pump technology.
- 15:27Speaker 2: Import regulations that facilitate access and public health campaigns to
- 15:31Speaker 2: educate both providers and patients. These could go a long
- 15:35Speaker 2: way in ensuring that the latest insulin technologies reach all
- 15:38Speaker 2: those who need them.
- 15:39Speaker 1: That's a solid approach. But let's not forget the ethical
- 15:44Speaker 1: implications of using advanced technologies. How do we balance the
- 15:48Speaker 1: benefits with the need to preserve natural biological processes?
- 15:53Speaker 2: Great point, Rachel. Ethical considerations are crucial. ensuring that the
- 15:58Speaker 2: use of artificial technologies enhances rather than undermines the natural
- 16:03Speaker 2: balance of the body. We need to involve diverse stakeholders, clinicians, ethicists,
- 16:09Speaker 2: patients in decision-making processes to ensure that these technologies are
- 16:13Speaker 2: developed and deployed responsibly.
- 16:15Speaker 1: Exactly. Which brings up an interesting contradiction. On one hand,
- 16:20Speaker 1: we have the potential to revolutionize diabetes management. But on
- 16:24Speaker 1: the other … We must ensure that these advancements don't
- 16:27Speaker 1: widen the gap between the privileged and the underserved.
- 16:31Speaker 2: That's a complex balance. But with thoughtful, collaborative approaches, we
- 16:36Speaker 2: can make strides in both technological innovation and equitable access,
- 16:40Speaker 2: ensuring that the millions affected by diabetes have the tools
- 16:43Speaker 2: they need to thrive.
- 16:45Speaker 1: So, there we have it. A century of incredible progress
- 16:49Speaker 1: in insulin treatment. From the humble beginnings at the University
- 16:53Speaker 1: of Toronto, to today's advanced technologies. The journey has been
- 16:58Speaker 1: nothing short of transformative.
- 17:00Speaker 2: Absolutely. It's fascinating to see how far we have come.
- 17:04Speaker 2: But with every step forward, Therese always a need to
- 17:06Speaker 2: look critically at the strategic implications. For instance, think about
- 17:11Speaker 2: the balance between innovation and ensuring that these advancements don't
- 17:15Speaker 2: widen the gap between the privileged and the underserved.
- 17:18Speaker 1: Exactly. We need to ensure that all stakeholders from researchers
- 17:21Speaker 1: to healthcare providers are working together to make these technologies
- 17:25Speaker 1: accessible to everyone. Take, for example, the impact of insulin pumps.
- 17:31Speaker 1: They offer a lot of flexibility, but they are not
- 17:34Speaker 1: as widely adopted as we might hope.
- 17:36Speaker 2: That's right. The complexity and cost of insulin pumps are
- 17:39Speaker 2: hurdles that many patients and healthcare systems face. It's a
- 17:43Speaker 2: reminder that while technology can be a game-changer, it must
- 17:47Speaker 2: be carefully implemented to avoid creating additional barriers.
- 17:51Speaker 1: And let's not forget about the environmental impact. The production
- 17:55Speaker 1: and disposal of these products, especially the single-use needles and pens,
- 17:59Speaker 1: have significant ecological consequences. We need to start thinking more
- 18:04Speaker 1: innovatively about reducing waste and improving sustainability.
- 18:08Speaker 2: Agreed. Speaking of sustainability, Taree's also a growing need to
- 18:13Speaker 2: address the economic disparities. Inulin formulations, while essential, are expensive,
- 18:19Speaker 2: which can create a huge burden for patients in lower
- 18:22Speaker 2: income regions. We need to find ways to make these
- 18:24Speaker 2: life-saving treatments more affordable.
- 18:27Speaker 1: Definitely. It's a complex issue, but one that demands urgent attention.
- 18:32Speaker 1: Collaboration between governments, NGOs, and the private sector will be
- 18:36Speaker 1: key in ensuring that everyone has access to the care
- 18:39Speaker 1: they need. One exciting area is the integration of advanced
- 18:43Speaker 1: technologies like continuous glucose monitoring and artificial intelligence. How do
- 18:49Speaker 1: you think these will play out in practice, Thomas?
- 18:52Speaker 2: Fascinating question. Imagine a future where insulin therapy becomes even
- 18:57Speaker 2: more personalized and efficient. AI could help predict insulin needs
- 19:02Speaker 2: based on real-time data, reducing the guesswork and improving overall management.
- 19:07Speaker 2: But we must ensure these tools are user-friendly and accessible
- 19:11Speaker 2: to all.
- 19:11Speaker 1: True. The key will be striking that balance between incorporating
- 19:15Speaker 1: cutting-edge technology and maintaining a patient-centric approach. It's not just
- 19:21Speaker 1: about the tech. It's about making sure it's user-friendly and
- 19:25Speaker 1: effective in the real world.
- 19:27Speaker 2: Exactly. And we shouldn't lose sight of the importance of
- 19:30Speaker 2: patient education and support systems. Diabetes management is a daily struggle,
- 19:35Speaker 2: and tools and resources that empower patients will be crucial.
- 19:38Speaker 1: Absolutely. It's a holistic approach that addresses the biological, technological,
- 19:44Speaker 1: and social aspects of diabetes treatment. Thanks for diving deep
- 19:48Speaker 1: into these issues with me. Thomas, it's clear that the
- 19:52Speaker 1: future of insulin therapy is bright but complex.
- 19:55Speaker 2: Couldn't agree more, Rachel. As we move forward, let's stay
- 19:59Speaker 2: vigilant and committed to making these advancements work for everyone.
- 20:02Speaker 2: If we do that, we can truly transform the lives
- 20:05Speaker 2: of millions.
- 20:06Speaker 1: That brings us to the end of today's episode. Thank
- 20:09Speaker 1: you so much for spending part of your day with me.
- 20:12Speaker 1: If you found this episode's tips helpful and want to
- 20:15Speaker 1: make sure you don't miss the next conversation, please take
- 20:18Speaker 1: a quick second to hit that subscribe or follow button
- 20:21Speaker 1: on whatever platform you are listening on. It's a completely
- 20:24Speaker 1: free way to support the show and helps more people
- 20:27Speaker 1: find us. This podcast is independently produced so if you
- 20:31Speaker 1: are ever in a position where you would like to
- 20:33Speaker 1: help keep it running, we do accept small donations. You
- 20:37Speaker 1: can find a link right in the episode description below
- 20:39Speaker 1: to buy us a coffee or contribute what you can.
- 20:42Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 20:47Speaker 1: and we will talk again soon.